45 results about "Adrenocortical hormone" patented technology

The invention discloses a traditional Chinese medicine decoction for treating female endocrine disorders and a preparation method thereof, belonging to the field of traditional Chinese medicines. The active ingredients of the medicine are prepared from the following raw material medicines in parts by weight: 40-60g of mulberry, 25-32g of astragalus, 20-27g of dogwood, 14-18g of root of rehmannia, 15-20g of the seed of Chinese dodder, 12-17g of Chinese angelica, 10-16g of salvia miltiorrhiza, 9-13g of medlar, 10-15g of cortex albiziae, 11-15g of honeysuckle, 8-12g of fallopia japonica, 7-10g of verbena officinalis, 8-11g of radix ophiopogonis, 6-10g of lalang grass rhizome, 5-10g of Chinese yam, 3-6g of fructus cnidii, 4-7g of donkey-hide gelatin, 2-4g of sea horse and 1-2g of poria cocos. The selected medicines are compatible in composition, multiple traditional Chinese medicinal materials are elaborately selected and matched aiming at characterizations of qi and blood stagnation, pathogenic toxin invasion and qi-blood deficiency causing endocrine disorders, yin nourishing treatment is performed according to aspects of excess, deficiency, yin, yang, qi and blood, the nervous system is regulated, a normal function state of the organism is restored, and the traditional Chinese medicine decoction has an excellent treatment effect on abnormal endocrine disorder symptoms of sex hormone, adrenocortical hormone, insulin and thyroid gland.

The invention discloses an application of Loureirin B in the preparation of a Kv1.3 channel blocker and provides a new drug approach for treating autoimmune diseases. The Loureirin B contains clear components and quality of the Loureirin B is controllable. The Loureirin B can effectively inhibit a Kv1.3 potassium channel, thus effectively treating various autoimmune diseases. Through various verification means of patch clamp experiment, calcium imaging techniques, ELISA assay and manufacturing of animal models of autoimmune encephalitis, rheumatoid arthritis and the like, it is found that the Loureirin B has a good therapeutical effect on autoimmune diseases at the overall level, can effectively overcome side effects of traditional therapeutics such as adrenocortical hormone and the like and can maintain normal protective immune responses of patients.

The invention relates to a preparation method of adrenocortical hormone agents, and particularly discloses a preparation method of (R)-budesonide. 11beta,21-dihydroxy-16alpha,17- [(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione is taken as an initial raw material, and the budesonide (R-isomer) is obtained through exchange and splitting. The preparation method of the (R)-budesonide is simple in process, high in yield and suitable for industrial production.

The invention belongs to the technical field of medicine compositions, and discloses an external use medicine composition used for treating alopecia. The external use medicine composition comprises annular adrenocorticotrophic hormone release factor (CRF) antagonism peptide astressin B in effective treatment amount or acceptable salt on the pharmacy. The external use medicine composition is in a gel dosage form preferably and suitable for clinic use and industrialization production. In addition, the invention further discloses a method for preparing the external use medicine composition and application of the astressin B in effective treatment amount or the acceptable salt on the pharmacy to preparing the external use medicine composition used for treating the alopecia. According to the external use medicine composition, the problem of the alopecia for a long time can be effectively treated; and the external use medicine composition is safe, reliable, free of obvious skin irritants and free of sensitization.

The invention relates to a method for alleviating on or more of the symptoms associated with menopause in a woman in the peri-menopause or menopause stage, said method comprising the step of administering a sensory regimen in an amount effective to downregulate the activity of the HPA axis of said woman; wherein said HPA axis comprises: a) levels of adrenocortical hormone present as a function of time in said woman; b) a total daily amount of adrenocortical hormone; c) an integrative measure of morning peak adrenocortical hormone; and d) an onset of sleep threshold; wherein said sensory regimen is selected from the group consisting of auditory stimuli, visual stimuli, tactile stimuli, gustatory stimuli, olfactory stimuli, and combinations thereof.

The present invention provides a method for efficiently inducing CD8-positive T cells by adding vitamin C to the medium in the steps of induction of the CD8-positive T cells from pluripotent stem cells. The present invention also provides a method for efficiently inducing CD8-positive T cells by performing culture in a medium supplemented with an adrenocortical hormone agent in the step of induction of the CD8-positive T cells from CD4/CD8 double-positive T cells.

The invention discloses combined application of statin and adrenocortical hormone medicaments to treatment of chronic subdural hematoma. Through combined application of the medicaments, hematoma absorption can be accelerated remarkably, the curative effect of other oral statins is improved greatly, and other side effects are avoided; moreover, the dosage of the adrenocortical hormone medicament is one tenth of the dosage of hormone, and the incidence of relevant complications caused by hormone treatment is lowered greatly. Through the technical scheme of combined application of the medicaments, a good curative effect is achieved, and wide application prospect and clinical significance are achieved.

The invention discloses a Chinese patent drug capable of replacing adrenocortical hormone to relieve nephritis and nephropathy. The Chinese patent drug comprises 150 parts of astragali radix, 30 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 30 parts of crude dragon bone, 30 parts of raw oyster, 30 parts of concha haliotidis, 15 parts of cuttlebone, 15 parts of radix rubiae, 12 parts of crinis trachycarpi, 30 parts of radix rehmanniae, 20 parts of rhizoma dioscoreae, 20 parts of semen euryales and 15 parts of loranthus parasiticus. The Chinese patent drug comprises various effective ingredients, has remarkable curative effects on urine protein, occult blood and various discomfort of edema, high blood pressure, swirl, headache, backache, nausea, anorexia and the like caused by nephropathy, adopts pure traditional Chinese medicines, and is free of hormone, toxic and side effect, adverse reaction, rapid in effect and low in cost.

The invention discloses a biscuit for children. The biscuit for children comprises the following raw materials in parts by weight: 20-50 parts of refined wheat powder, 20-30 parts of pumpkin powder, 10-15 parts of hydrolyzed milk, 10-20 parts of fruit and vegetable juice, 15-25 parts of protein powder, 5-10 parts of butter, 1-2 parts of sodium bicarbonate, 3-10 parts of yeast, 10-20 parts of maplesugar and 2-5 parts of salt. The butter and hydrolyzed milk are mixed and stirred for 10 minutes, are added with eggs, the salt, the maple sugar and the fruit and vegetable juice, and then are stirred for 5 minutes to obtain a mixed solution. The pumpkin powder and the maple sugar are added to process the biscuit for children, and the pumpkin has high nutritive value, contains abundant zinc, participates in synthesis of nucleic acid and protein in human bodies, is an inherent ingredient of adrenocortical hormone, is an important substance for growth and development of human bodies, and is exactly suitable for growth and development of the children.

The invention belongs to the technical field of biological medicine, and discloses three groups of siRNAs targeting human and mouse CRH genes and application thereof in treatment of neuropathic pain. The three groups of siRNAs targeting the CRH genes (adrenocorticotropic hormone-releasing hormone) are designed and synthesized, the three groups of siRNAs are intrathecally injected into a neuropathic pain model mouse during in-vivo experiments. Molecular biology experiments show that the two groups of siRNAs can block CRH expression increase induced by nerve injury in mouse dorsal root ganglion (DRG) in vivo, and show that the two groups of siRNAs can effectively reduce CRH gene expression, but the effect of the second group is more obvious. Pain behavioral detection shows that the neuropathic pain can be effectively relieved through intrathecal injection of the second group of CRH siRNA. The invention provides non-chemical modification and chemical modification nucleic acid molecules of the targeted CRH gene, has a better treatment effect on neuropathic pain, provides a new thought and experimental basis for clinical research and development of new analgesic drugs, and has important clinical application value.

The object of the present invention is to provide an olfactory disturbance therapeutic agent that is effective in repairing or regenerating olfactory epithelium that suffered damages such as scratches and can be administered for a long time.

The object of the present invention is achieved by an olfactory disturbance therapeutic agent including at least one active ingredient that is selected from among a group consisting of insulin, insulin analogs, and insulin secretagogues. Preferably, the olfactory disturbance therapeutic agent is used for people with olfactory disturbance who have, or are at risk of having, impaired insulin secretion or insulin resistance, or for people who could suffer an iatrogenic increase in blood sugar level or a disturbance in a balance of adrenocortical hormone stemming from a long-term use of steroid as olfactory disturbance treatment.

A method of affecting sleep and sleep-related behaviors of a mammal having a diurnal rhythm, by reducing the basal activity of the hypothalamus-pituitary-adrenal axis by administering an effective amount of a sensory regimen is disclosed. Such reduction may be accomplished by reducing at least one of the following: a. the average total daily amount of adrenocortical hormone; or b. the average total daily amount adrenocortical hormone minus the integrative measure of morning peak adrenocortical hormone. Preferably, such reduction also includes reducing at least one of the following: c. the level of adrenocortical hormone 4 hours to 8 hours after waking; d. the level of adrenocortical hormone in the period of time preceding bedtime; or e. the level of adrenocortical hormone below the onset of sleep threshold.